John Deedrick - Xtant Medical Independent Director
| XTNT Stock | USD 0.85 0.01 0.98% |
Director
Mr. John Deedrick is an Independent Director of Bacterin International Holdings, Inc. Mr. Deedrick is an experienced senior executive with 15 years experience in healthcare VC and business consulting. Mr. Deedrick also has 12 years of experience in the high tech defense industry. He has served as a corporate VCist for Mayo Clinic and a Founder and General Partner for Accuitive Medical Ventures. Mr. Deedrick also serves as President and CEO of CHIP Solutions and is Founder and Chairman of GreatDeeds, a Minnesota nonprofit organization. Mr. Deedrick has served on the board of numerous early stage healthcare companies over the last 15 years. Mr. Deedrick received his undergraduate degree from Northwestern College and his MBA from St. Thomas University . Mr. Deedrick contributes significant financial, management and industry experience to the Board of Directors. since 2013.
| Age | 51 |
| Tenure | 11 years |
| Address | 664 Cruiser Lane, Belgrade, MT, United States, 59714 |
| Phone | 406 388 0480 |
| Web | https://www.xtantmedical.com |
Xtant Medical Management Efficiency
The company has return on total asset (ROA) of (0.0831) % which means that it has lost $0.0831 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0154 %, meaning that it created $0.0154 on every $100 dollars invested by stockholders. Xtant Medical's management efficiency ratios could be used to measure how well Xtant Medical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Xtant Medical's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.15) in 2024. Change To Liabilities is likely to gain to about 1.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 16 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jay Kunkel | Varex Imaging Corp | 58 | |
| Steven Loranger | Edwards Lifesciences Corp | 69 | |
| Erich Reinhardt | Varex Imaging Corp | 71 | |
| William Link | Edwards Lifesciences Corp | 73 | |
| William Eckles | Electromed | 42 | |
| Nicholas Valeriani | Edwards Lifesciences Corp | 64 | |
| Martha Marsh | Edwards Lifesciences Corp | 72 | |
| Ramona Sequeira | Edwards Lifesciences Corp | 55 | |
| Paul LaViolette | Edwards Lifesciences Corp | 63 | |
| Angela Fuente | Edwards Lifesciences Corp | N/A | |
| Howard Goldman | Varex Imaging Corp | N/A | |
| David Holtz | Dynatronics | 51 | |
| Leslie Heisz | Edwards Lifesciences Corp | 60 | |
| Stephen Ondra | Electrocore LLC | N/A | |
| Stan Erickson | Electromed | 66 | |
| John Cardis | Edwards Lifesciences Corp | 73 | |
| Nick Colucci | Electrocore LLC | N/A | |
| Lee Jones | Electromed | 60 | |
| Erin Enright | Dynatronics | 56 | |
| Jocelyn Chertoff | Varex Imaging Corp | 62 | |
| Wesley Schack | Edwards Lifesciences Corp | 74 | |
Management Performance
| Return On Equity | 0.0154 | ||||
| Return On Asset | -0.0831 |
Xtant Medical Holdings Leadership Team
Elected by the shareholders, the Xtant Medical's board of directors comprises two types of representatives: Xtant Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Xtant. The board's role is to monitor Xtant Medical's management team and ensure that shareholders' interests are well served. Xtant Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Xtant Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sean Browne, CEO President | ||
| Kevin Brandt, Senior Vice President Chief Commercial Officer | ||
| Kevin ODare, VP US | ||
| Rudy Mazzocchi, Independent Director | ||
| David Goodman, Independent Director | ||
| David Kirschman, Director | ||
| Ronald Berlin, COO, Vice President | ||
| Robert Silvio, President | ||
| Jill Gilpin, General Counsel | ||
| Paul Buckman, Independent Director | ||
| John Bakewell, Director | ||
| Robert McNamara, Director | ||
| John Deedrick, Independent Director | ||
| Gregory Juda, Chief Scientific Officer | ||
| Greg Jensen, Principal Executive Officer, Interim CFO, Vice President - Finance | ||
| Michael Lopach, Independent Director | ||
| Kent Swanson, Independent Chairman of the Board | ||
| Mark Schallenberger, Chief Officer | ||
| Catherine Lundy, Vice Resources | ||
| Matthew Rizzo, Director | ||
| Kathie Lenzen, CFO, Senior Vice President - Finance and Administration | ||
| Michael Mainelli, Director | ||
| Darrel Holmes, COO | ||
| Jon Wickwire, Independent Director | ||
| Michael Eggenberg, Director | ||
| John Gandolfo, CFO | ||
| Scott Neils, Chief Officer | ||
| Daniel Goldberger, CEO and Director | ||
| Eric Timko, Independent Director | ||
| Carl OConnell, President | ||
| Jeffrey Peters, Director | ||
| Rich Cockrell, IR Contact Officer |
Xtant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Xtant Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0154 | ||||
| Return On Asset | -0.0831 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 130.34 M | ||||
| Shares Outstanding | 130.22 M | ||||
| Shares Owned By Insiders | 8.30 % | ||||
| Shares Owned By Institutions | 69.29 % | ||||
| Number Of Shares Shorted | 260.86 K | ||||
| Price To Earning | (0.41) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Xtant Medical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Xtant Medical's short interest history, or implied volatility extrapolated from Xtant Medical options trading.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Xtant Medical Holdings is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Xtant Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Xtant Medical Holdings Stock. Highlighted below are key reports to facilitate an investment decision about Xtant Medical Holdings Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xtant Medical Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Xtant Stock analysis
When running Xtant Medical's price analysis, check to measure Xtant Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xtant Medical is operating at the current time. Most of Xtant Medical's value examination focuses on studying past and present price action to predict the probability of Xtant Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xtant Medical's price. Additionally, you may evaluate how the addition of Xtant Medical to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Xtant Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xtant Medical. If investors know Xtant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xtant Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.01 | Revenue Per Share 0.767 | Quarterly Revenue Growth 0.841 | Return On Assets (0.08) | Return On Equity 0.0154 |
The market value of Xtant Medical Holdings is measured differently than its book value, which is the value of Xtant that is recorded on the company's balance sheet. Investors also form their own opinion of Xtant Medical's value that differs from its market value or its book value, called intrinsic value, which is Xtant Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xtant Medical's market value can be influenced by many factors that don't directly affect Xtant Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Xtant Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Xtant Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xtant Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.